ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1387	National Cancer Institute	Html	en	Breast Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for breast cancer are female sex and advancing age, inherited risk, breast density, obesity, alcohol consumption, and exposure to ionizing radiation. Interventions to prevent breast cancer include chemoprevention (e.g. SERMs, AIs), risk-reducing surgery (e.g. mastectomy, oophorectomy). Review the evidence on risk factors and interventions to prevent breast cancer in this expert-reviewed summary.	Surgical Adjuvant Breast 0.484835 situ breast cancer 0.497037 Breast Cancer Intervention 0.493501 breast cancer trends 0.484079 breast cancer deaths 0.490132 radiation-associated breast cancer 0.489257 Engl J Med 0.493511 post-menopausal breast cancer 0.480461 Breast Cancer Surveillance 0.4815 breast cancer incidence. 0.495634 treatment-related breast cancer 0.489379 early-stage breast cancer 0.507669 fatal breast cancer 0.490061 ER-positive breast cancer 0.490928 breast cancer prevention 0.509672 Breast Cancer Collaborative 0.483305 breast cancer patients 0.502781 postmenopausal breast cancer 0.486608 therapy-related breast cancer 0.480826 breast cancer risk. 0.512722 Natl Cancer Inst 0.684414 -negative breast cancer 0.484014 breast cancer death 0.482095 invasive breast cancer 0.614612 et al. 0.488773	Swedish breast cancer 0.480364 women 0.553885 contralateral breast cancer 0.510667 early breast cancer 0.491581 age-specific breast cancer 0.483209 breast cancer susceptibility 0.482582 breast cancers 0.487583 age-adjusted breast cancer 0.485699 breast cancer rates 0.491912 human breast cancer 0.484504 tamoxifen breast cancer 0.487689 Female Breast Cancer 0.482581 postmenopausal women 0.549947 breast cancer risk 0.650399 International Breast Cancer 0.494317 Abstract 0.524687 breast cancer 0.96573 breast cancer mortality 0.521549 breast cancer cases 0.492675 Breast Cancer Study 0.481834 ER-negative breast cancer 0.487382 breast cancer incidence 0.616078 elevated breast cancer 0.489604 Excess breast cancer 0.489271	CLICK HERE
1503	National Cancer Institute	Html	en	Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of ovarian germ cell tumors.	adjuvant chemotherapy 0.587693 pure dysgerminoma 0.480069 Oncology Group trials 0.399123 endodermal sinus tumor 0.426786 chemotherapy 0.67435 PDQ cancer information 0.453857 incompletely resected tumors 0.456006 cancer information summary 0.450698 high-dose chemotherapy 0.414186 recurrent germ cell 0.415503 durable remission 0.43875 radiographic procedures 0.437608 para-aortic lymph nodes 0.495597 patients 0.944817 intact ovary 0.411146 Surgical resection 0.432079 adjuvant therapy 0.398709 higher stage tumors 0.443399 total abdominal hysterectomy 0.474933 Gynecologic Oncology Group 0.490243 Endodermal sinus tumors 0.452987 radiation therapy 0.487845 immature teratoma 0.464025 modern chemotherapeutic era 0.398622 advanced stage dysgerminoma 0.404048	ovarian germ cell 0.413493 clinical examination 0.424181 primary tumor. 0.431827 residual masses 0.43388 well-staged patients 0.406144 fallopian tube 0.401507 completely resected tumors 0.468623 BEP combination chemotherapy 0.509951 cisplatin-based adjuvant treatment. 0.511465 maximal surgical debulking 0.469791 adjuvant setting 0.44443 endodermal sinus 0.463622 Second-look surgery 0.421726 disease 0.413051 large tumors 0.399492 mixed germ cell 0.430258 combination chemotherapy 0.637036 salvage therapy. 0.435874 cisplatin-containing combination chemotherapy 0.471327 stage IA tumors 0.445257 germ cell tumors 0.871083 stage 0.462819 initial surgical procedure 0.530199 Cisplatin-based combination chemotherapy 0.476734	CLICK HERE
1504	National Cancer Institute	Html	en	Carcinoma of Unknown Primary Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor.	prostate cancer-specific tests 0.758495 moderately differentiated tumors 0.76812 primary breast cancer 0.810157 CUP tumors 0.744436 germ cell tumor 0.900926 unguided clinical evaluation 0.74246 primary tumor origin. 0.829274 lung cancer 0.758661 major primary adenocarcinomas 0.79306 bone metastases 0.787576 CUP 0.964346 unguided radiographic studies 0.740775 patients 0.907112 poorly differentiated tumor 0.786876 poor prognostic finding. 0.745421 fine-needle aspiration biopsy 0.740303 axillary metastasis 0.759204 stage information section 0.75285 primary site 0.901386 primary malignancy 0.785612 primary disease 0.779121 lung metastases 0.79491 primary sites 0.766562 treatable primary cancers. 0.775244	CUP patients 0.753414 primary manifestation 0.731878 special diagnostic pathology 0.734268 Lymph node involvement 0.737229 pancreatic cancer 0.758796 Breast Cancer Treatment 0.769987 different metastatic distribution 0.743182 single study 0.73541 complete blood cell 0.762048 predominant bony distribution 0.735381 midline germ cell 0.743808 noncarcinoma cell type 0.749494 breast cancer 0.825399 certain clinical presentations 0.748925 primary tumor 0.992795 prostate cancer 0.879535 supradiaphragmatic primary malignancy 0.778764 significant prognostic importance 0.741352 potential primary lesion 0.812433 appropriate clinical evaluation 0.754068 occult primary tumor 0.820012 End Results data 0.738986 common primary carcinomas 0.811152 primary prostate cancer. 0.808097	CLICK HERE
1533	National Cancer Institute	Html	en	Cancell/Cantron/Protocel (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Cancell/Cantron/Protocel as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	peer-reviewed scientific journals 0.623029 NCI Tumor Cell 0.661367 cell lines 0.687144 human cells 0.635256 aerobic metabolism 0.794285 bacterium P. cryptocides. 0.62979 PDQ cancer information 0.88904 cancer development. 0.663979 vitro NCI-60 DTP 0.62954 somewhat different explanations 0.628856 Cancer Terms 0.627276 principal manufacturers 0.71541 certain damaging conditions 0.634012 Topical skin application 0.63342 substantial antitumor activity. 0.625666 cancer information summary 0.875855 breast cancer prevention 0.656117 Tumor Cell Line 0.74552 clinical drug research 0.64982 Cancell/Cantron/Protocel 0.841588 Investigational New Drug 0.649141 cancerous cells 0.717346 NCI’s PDQ 0.624803 NCI PDQ cancer 0.71862	residual aerobic metabolism 0.655098 NCI Dictionary 0.62162 unapproved new drug 0.650693 numerous animal experiments 0.621001 completely primitive state 0.63055 Therapies Editorial Board 0.638692 vivo situation 0.631095 excretion—an unlikely situation 0.620899 original manufacturer 0.721066 cancer cells 0.761265 damaged normal cells 0.711253 critical point 0.644689 reference citations 0.63628 idealized conditions Cancell/Cantron/Protocel 0.671023 adult-onset diabetes mellitus 0.639765 additional biochemical reactions 0.628258 cell line screen 0.841075 National Cancer Institute 0.793891 NCI human cancer 0.696144 normal cells 0.997775 chronic energy stress 0.639389 Human Tumor Cell 0.638074 cancer information summaries 0.702185 artificial media 0.635059	CLICK HERE
1586	National Cancer Institute	Html	en	Vaginal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of vaginal cancer.	cell vaginal cancer 0.360195 lymph node dissection 0.326781 body 0.312996 abnormal areas 0.281727 PDQ cancer information 0.334259 vaginal cancer 0.760063 clinical trial search 0.36299 clinical trials 0.668187 cancer information summary 0.310305 clinical trial 0.454575 squamous cell cancer 0.354582 Vaginal Cancer Treatment 0.308045 Pap test 0.272131 patients 0.293377 IVB vaginal cancer 0.318217 NCI PDQ cancer 0.278314 malignant tumor cells 0.275963 Treatment Option Overview 0.274359 lymph nodes 0.290946 radiation therapy 0.589716 General information 0.282628 general cancer information 0.271401 treatment 0.460915 abnormal cells 0.349727 wide local excision 0.321438	Recurrent vaginal cancer 0.337303 new cancer treatments 0.27048 NCI-supported cancer 0.305828 cancer cells 0.3346 vaginal intraepithelial neoplasia 0.296856 Cancer Information Service 0.272009 vaginal cancer spreads 0.334927 squamous cell 0.369952 stage ivb 0.271421 treatment clinical trials 0.293735 National Cancer Institute 0.348129 tumor cells 0.290691 new treatment 0.303739 cervix 0.280807 IVA vaginal cancer 0.291708 external radiation therapy 0.454541 cancer clinical trials 0.3729 cells 0.353506 stage 0.310322 cancer information summaries 0.270039 comprehensive cancer information 0.270279 internal radiation therapy 0.457186 Cervical Cancer Treatment 0.289689 cancer 0.911572	CLICK HERE
1770	National Cancer Institute	Html	es	Prurito (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del prurito (picazón en la piel) como complicación del cáncer o su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.	haemodialysis patients 0.476654 Section XII 0.477073 Rubenstein E 0.559292 Sin embargo 0.803552 Scientific American Medicine 0.676981 categoría farmacológica medicamento 0.526417 Am Acad Dermatol 0.571569 Clin Res 0.479277 Wolff K 0.536775 Acad Dermatol Venereol 0.493209 Farber EM 0.55456 patients with atopic 0.550773 Cancer Nursing 0.471101 PDQ Prurito 0.665745 Dermatol Venereol Leprol 0.6251 with atopic dermatitis 0.566467 toxina botulínica 0.473345 reacciones cutáneas 0.538217 patients with 0.621762 chronic idiopathic 0.533598 Pain Symptom Manage 0.649291 neuropathic pruritus 0.513717 Scientific American 0.875762 Oncol Nurs Forum 0.782558 Malignant cutaneous tumors 0.546882	Dosis Comentarios Referencias 0.53479 General Medicine 0.52531 terminal cancer patient 0.535978 All Free Clear 0.515267 Dermatol Venereol 0.632286 farmacológica medicamento dosis 0.550466 Clinical aspects 0.477546 Medicamento Dosis Comentarios 0.541353 Acta Derm Venereol 0.979711 Eisen AZ 0.543793 New York 0.832579 patients receiving 0.483634 Yosipovitch G 0.516371 mg diarios comenzar 0.507465 Abel EA 0.553787 Enterostomal Ther 0.474722 sistema nervioso central 0.522009 pruritus relief with 0.489446 policitemia vera 0.673444 Dermatol Ther 0.602936 Fitzpatrick TB 0.546636 Federman DD 0.567864 Bernhard JD 0.556935 chronic pruritus 0.522206	CLICK HERE
1857	National Cancer Institute	Html	es	Tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto.	ominosa situación 0.323583 microscopic findings with 0.340934 poorly differentiated tumors 0.343157 cisplatin-based combination chemotherapy 0.340177 unknown primary site 0.370765 N)a aReproducción 0.321827 Instituto Nacional 0.378061 Radiat Oncol Biol 0.947729 bUna designación 0.320629 emission tomography with 0.337851 Diagn Pathol 0.32218 chemoradiotherapy using 0.320607 solid tumors 0.321716 Acta Cytol 0.320567 Head Neck Surg 0.377028 primary site 0.383303 after excisional biopsy 0.335976 metastases from 0.417556 dysfunction following radiotherapy 0.335828 carcinoma nasofaríngeo 0.419271 Kahn HJ 0.320427 paciente varón 0.325653 cervical lymph 0.356026 Recent progress 0.321743 intensity-modulated radiotherapy 0.356033	Cheung R 0.361917 from unknown primary 0.367172 National Cancer Institute 0.343401 PDQ Tratamiento 0.380147 nasopharyngeal carcinoma 0.428219 Lombardi Comprehensive Cancer 0.345987 Clin Oncol 0.335468 unknown primary 0.700357 Physician Data Query 0.330819 enfermedad n2 0.320558 Oncol Biol Phys 0.999042 enfermedad n1 0.322779 largo plazos 0.351849 metastatic adenocarcinomas 0.360803 unknown primary tumor 0.440765 Induction chemotherapy with 0.342645 Gray GF Jr 0.331989 neck cancer 0.546903 American Joint Committee 0.331644 Reimann BE 0.320391 Miyazaki I 0.364645 AJCC Cancer Staging 0.353491 squamous cell carcinoma 0.742589 solitary metastatic neck 0.365007	CLICK HERE
1954	National Cancer Institute	Html	es	Tratamiento del mesotelioma maligno (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesotelioma maligno.	siguientes procedimientos 0.614487 estadio iv 0.791187 Malignant Mesothelioma 0.549358 estadio ii 0.653957 estadios ia 0.559097 vía oral 0.54921 rayos x 0.916803 estadio ib 0.585037 enlace drugs approved 0.58335 estadio ia 0.583181 ondas sonoras 0.565775 líquido anormales.ampliar biopsia 0.679304 siguientes síntomas 0.602559 National Cancer Institute 0.545373 siguientes riesgos 0.53912	siguientes tratamientos 0.580411 quimioterapia intraperitoneal hipertérmica 0.640252 detalles minúsculos 0.572451 Instituto Nacional 0.580849 PDQ Tratamiento 0.591752 alta potencia 0.560897 presente sección 0.540992 partes distantes 0.551484 Physician Data Query 0.667975 siguientes sitios 0.687794 pequeña incisión 0.582002 ecografía ayuda 0.565218 cuerpo llamada ecograma 0.656058 siguientes pruebas 0.740981	CLICK HERE
3879	National Cancer Institute	Html	es	Extractos de muérdago (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.	cuerpo frente 0.413451 Centro Nacional 0.449381 New Hampshire Avenue 0.415853 cabo ensayos 0.424385 Drug Administration 0.409825 NCI Best Case 0.428572 PDQ Extractos 0.439937 Helixor A 0.41291 datos bibliográficos pubmed 0.416761 marcas comerciales eurixor 0.426376 siguientes preguntas 0.410006 productos botánicos 0.410905 Polyerga Neu 0.415135 solicitudes ind 0.41359 cura lotodo 0.415539 vitamina b 0.413657 siguientes riesgos 0.412404 Instituto Nacional 0.532861 National Center 0.412812	siguientes marcas 0.416399 Salud Complementaria 0.466538 idioma alemán 0.413696 Visuals Online 0.41151 complementarias revisa 0.415619 Physician Data Query 0.465832 Estados Unidos 0.692378 mejores cuidados 0.41274 libre uso 0.41183 cabo estudios 0.418615 Integrative Health 0.413952 página manejo 0.410784 ¿El tratamiento 0.420943 ¿Los beneficios 0.40989 juntos cam 0.409184 respuesta corporal frente 0.42523 Series Program 0.409771 medicina complementaria 0.946895 árbol hospedador 0.450028	CLICK HERE
3899	National Cancer Institute	Html	en	National Cancer Act of 1937	National Cancer Act of 1937, signed into law by President Franklin D. Roosevelt, created the National Cancer Institute.	general public 0.367365 National Cancer Advisory 0.528357 cancer control work 0.436895 research projects 0.391515 act 0.566247 similar research 0.476584 General its approval 0.365736 federal government 0.49191 Cancer Institute Act 0.442221 appointed member 0.370413 National Advisory Cancer 0.52537 technical matters 0.410467 prevention 0.411559 human knowledge 0.397925 diagnosis 0.527183 non-communicable disease 0.363394 Cancer Advisory Council 0.437071 PUBLIC NO. 0.367229 independent research institute 0.437264 principal agency 0.418501 similar research activities 0.412381 treatment centers 0.373224 National Cancer Act 0.475787 treatment 0.554492 valuable contributions 0.393688	United States 0.637137 methods 0.412995 Institute consultation services 0.410647 cause 0.426942 training 0.369834 Advisory Cancer Council 0.524827 cancer research 0.428314 private institutions 0.416999 Franklin D. Roosevelt 0.416988 Public Law 0.367866 cancer experts 0.38424 State health agencies 0.402781 National Cancer Institute 0.913007 official business 0.397421 research institutions 0.36768 Committee Report No. 0.406179 approval 0.369507 HR.7931. 75th Congress 0.4075 acceptance conditional gifts 0.395258 Cancer Investigations 0.395678 Surgeon General 0.940401 Public Health Service 0.694963 75th congress 0.416285 time 0.374442	CLICK HERE